Optimization and Formulation of Orodispersible Tablets of Meloxicam
AbstractPurpose: The objective of this study was to formulate and optimize an orodispersible formulation of meloxicam using a 22 factorial design for enhanced bioavailability.
Methods: The tablets were made by non-aqueous wet granulation using crospovidone and mannitol. A 22 factorial design was used to investigate the amount of crospovidone and taste masking, soothening hydrophilic agent (mannitol), as independent variables, and disintegration time as dependent response. Formulated orodispersible tablets were evaluated
for weight variation, friability, disintegration time, drug content, wetting time, water absorption ratio and in vitro drug release.
Results: The results show that the presence of a superdisintegrant and mannitol is desirable for orodispersion. All the formulations satisfied the limits of orodispersion with a dispersion time of less than 60 sec. For example, formulation F4 showed a disintegration time of 32.1
sec, crushing strength of 4.93 kg/cm2, drug content of 98.5% and fast drug release rate of 99.5% within 30 min, as compared with the conventional tablet (49.5%) .
Conclusion: It is feasible to formulate orodispersible tablets of meloxican with acceptable disintegration time, rapid drug release and good hardness, which could be amenable to replication on an industrial scale.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.